Biological Materials Related to C-Met

Sanofi

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 10 of these applications claim priority to application 61/500,464, filed Jun 23, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Patent	Title	Holder	Status	Expires	Time remaining	Confidence
US 8,703,135	Biological Materials Related to C-Met Sanofi In force Term ends Sep 30, 2031 · High confidence	Sanofi	In force	Term ends Sep 30, 2031	Term ends Sep 30, 2031	High confidence
US 9,573,992	Serum Albumin Binding Proteins Sanofi In force Term ends Sep 30, 2031 · High confidence	Sanofi	In force	Term ends Sep 30, 2031	Term ends Sep 30, 2031	High confidence
US 9,683,045	Biological Materials Related to C-Met Sanofi In force Term ends Sep 30, 2031 · High confidence	Sanofi	In force	Term ends Sep 30, 2031	Term ends Sep 30, 2031	High confidence
US 10,858,418	Techniques for Predicting, Detecting and Reducing Aspecific Protein Interference in Assays Involving Immunoglobulin Single Variable Domains Sanofi In force Term ends Sep 30, 2031 · High confidence	Sanofi	In force	Term ends Sep 30, 2031	Term ends Sep 30, 2031	High confidence
US 11,192,937	Techniques for Predicting, Detecting and Reducing Aspecific Protein Interference in Assays Involving Immunoglobulin Single Variable Domains Sanofi In force Term ends Sep 30, 2031 · High confidence	Sanofi	In force	Term ends Sep 30, 2031	Term ends Sep 30, 2031	High confidence
US 11,192,938	Serum Albumin Binding Proteins Containing Immunoglobulin Single Variable Domains Sanofi In force Term ends Sep 30, 2031 · High confidence	Sanofi	In force	Term ends Sep 30, 2031	Term ends Sep 30, 2031	High confidence
US 11,644,471	Techniques for Predicting, Detecting and Reducing Aspecific Protein Interference in Assays Involving Immunoglobulin Single Variable Domains Sanofi In force Term ends Sep 30, 2031 · High confidence	Sanofi	In force	Term ends Sep 30, 2031	Term ends Sep 30, 2031	High confidence
US 12,006,352	Techniques for Predicting, Detecting and Reducing Aspecific Protein Interference in Assays Involving Immunoglobulin Single Variable Domains Sanofi In force Term ends Sep 30, 2031 · High confidence	Sanofi	In force	Term ends Sep 30, 2031	Term ends Sep 30, 2031	High confidence
US 12,630,609	Techniques for Predicting, Detecting and Reducing Aspecific Protein Interference in Assays Involving Immunoglobulin Single Variable Domains Sanofi In force Term ends Sep 30, 2031 · High confidence	Sanofi	In force	Term ends Sep 30, 2031	Term ends Sep 30, 2031	High confidence
US 12,662,525	Techniques for Predicting, Detecting and Reducing Aspecific Protein Interference in Assays Involving Immunoglobulin Single Variable Domains Sanofi In force Term ends Nov 17, 2031 · Medium confidence	Sanofi	In force	Term ends Nov 17, 2031	Term ends Nov 17, 2031	Medium confidence
5 more patents in this group · Pro

10 of 15 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Pro members see all 15.

Upgrade to Pro

11 of these are in force and held by Sanofi.

Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.